Login
$INDP
$3.34 +$0.01 (0.3%) Close

Company Executives

Officer Age In this role Joined Pay Source
Junyi Dai Also a director
Chief Executive Officer and Chairman of the Board
39 Not stated Not stated Not reported
Yu Ding
Chief Financial Officer
51 Since 2026
this year
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Jul 16, 2026 · updated by the 8-K of Sep 4, 2026

Directors
5
serving now
Independent
0 of 1
stated in the proxy; 4 not stated
Average tenure
0.0 years
from year joined
CEO also chairs the board
Yes
Junyi Dai
Director Age On board Independent Committees Other public boards Pay Source
Junyi Dai
39 2026
this year
Not independent None stated None stated Paid as CEO
David Natan
73 2026
this year
Not stated None stated Sunshine Biopharma, Inc. (Nasdaq: SBFM) Not stated
Johnny Fox Arrowsmith
48 2026
this year
Not stated
Nominating
None stated Not stated
Jerome Jabbour
52 2026
this year
Not stated
Compensation · Chair
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) Not stated
Qinglai Lu
48 2026
this year
Not stated
Nominating · Chair
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Mr. Ben-Tzvi
former director of the Company; entity owned by his spouse in which he has an indirect pecuniary interest
$41,000 per year in consulting fees

Consulting agreement for general business advice and services, with $41,000 per year in consulting fees, a $50,000 signing bonus and 25,000 restricted shares

With N.L.T. Management and Asset Holdings Company Ltd. Open in proxy
Matthew McMurdo
former director of the Company; Vice President, New Strategies
$41,000 per year in salary

Employment agreement as Vice President, New Strategies, with $41,000 per year in salary, a $50,000 signing bonus and 25,000 restricted shares

Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014; Yehuda Shimoni; Thomas Mollick
beneficial owners of more than 5% of our outstanding shares
Amount not stated
2026

Warrant repricing agreements reducing exercise prices of warrants to $1.75 and a voting agreement for the February 26, 2026 special meeting

With the Company Open in proxy
Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014; Yehuda Shimoni; Thomas Mollick
beneficial owners of more than 5% of our outstanding shares
Amount not stated
2025

Purchase of common stock and warrants in the January 2025 Private Placement

With the Company Open in proxy
Jeffrey Meckler
then Chief Executive Officer and director
Amount not stated
2025

Purchase of 6,068 shares and warrants to purchase 12,136 shares in the June 2025 Private Placement upon note conversion

With the Company Open in proxy
Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014; Yehuda Shimoni; Thomas Mollick
beneficial owners of more than 5% of our outstanding shares
Amount not stated
2025

Purchase of common stock, pre-funded warrants and warrants in the June 2025 Private Placement upon note conversion

With the Company Open in proxy
Jeffrey Meckler
then Chief Executive Officer and director
Amount not stated
2024

Purchase of 1,519 shares and warrants to purchase 1,519 shares in the November 2024 Financing

With the Company Open in proxy
Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014; Yehuda Shimoni; Thomas Mollick
beneficial owners of more than 5% of our outstanding shares
Amount not stated
2024

Purchase of common stock and warrants in the November 2024 Financing

With the Company Open in proxy
Jeffrey Meckler
then Chief Executive Officer and director
Amount not stated
2024

Purchase of 3,033 shares and warrants to purchase 3,033 shares in the August 2024 Financing

With the Company Open in proxy
Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014; Thomas Mollick
beneficial owners of more than 5% of our outstanding shares
Amount not stated
2024

Purchase of common stock and warrants in the August 2024 Financing

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support